Rituxan in combination with glucocorticoids (GCC) is the first FDA-approved medicine for people ages 2 years and above with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
Rituxan only targets a specific type of white blood cell found in the immune system. These cells are known as CD20+ B-cells and are thought to be involved in GPA and MPA. Rituxan targets these cells and is thought to reduce their levels in the body.
Because it is thought to interfere with B-cell function and disrupt ANCA production, Rituxan works differently from other medications used to treat GPA and MPA.
ANCA, antineutrophil cytoplasmic antibody.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.